Publications
197
Citations
3,413
Est. group size
—
Recurring co-author estimate
Active years
23
Publishing since 2004
Eric S. Orman studies liver disease, particularly advanced (decompensated) cirrhosis and its complications, such as acute kidney injury, hepatorenal syndrome, and infections. His work spans clinical trials of new drugs (for example terlipressin and integrin inhibitors), large multicenter observational studies, patient quality-of-life and caregiver research, and clinical practice guidelines. He also examines liver transplantation outcomes and models of care such as transitional liver clinics.
Publication activity has been steady to growing over the past decade, with a notable peak in 2020 and consistently high output in recent years (roughly 16 papers per year over the last five years).
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- IMPACTO DE LAS INFECCIONES BACTERIANAS EN PACIENTES CON CIRROSIS DESCOMPENSADA E INSUFICIENCIA RENAL AGUDA. UN SUBANÁLISIS DEL ICA-AKI GLOBAL STUDY
Gastroenterología y Hepatología · 2026
- Caregiver Involvement and Burden and Patient Quality of Life in Patients with Decompensated Cirrhosis
The American Journal of Gastroenterology · 2026
- The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial
Hepatology Communications · 2026
- OS-043-YI Clinical impact of non selective beta-blockers in patients with cirrhosis and acute kidney injury: a post hoc analysis of the international club of ascites GLOBAL-AKI study
Journal of Hepatology · 2025
- Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis
Journal of Hepatology · 2025
- Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Liver Transplantation · 2025
- AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review
Gastroenterology · 2025
- Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome
Clinical Gastroenterology and Hepatology · 2025
- Real-world practice patterns on the use of terlipressin in patients with cirrhosis and acute kidney injury - results from the ICA-GLOBAL AKI study
Digestive and Liver Disease · 2025
- Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis
Alimentary Pharmacology & Therapeutics · 2025
- FP7 Bexotegrast improves markers and symptoms of cholestasis and stabilizes markers of liver fibrosis in participants with primary sclerosing cholangitis
2025
- Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30
RWTH Publications (RWTH Aachen) · 2025
- Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study
The Lancet. Gastroenterology & hepatology · 2025
- TOP-062 Global epidemiology of acute kidney injury in hospitalized patients with cirrhosis: the ICA-GLOBAL AKI study
Journal of Hepatology · 2024
- TOP-064-YI Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide-analysis of the ICA-GLOBAL AKI study
Journal of Hepatology · 2024
- Gastroenterology×28
- The American Journal of Gastroenterology×18
- UNC Libraries×11
- Journal of Hepatology×10
- PMC×9
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile